logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Pralsetinib for treating thyroid cancer

< Back

Pralsetinib for treating thyroid cancer

Drugs

Cancer and Palliative Care

October 2021


Pralsetinib is in clinical development for the treatment of thyroid cancer. Thyroid cancer is a rare type of cancer that affects the thyroid gland, a small gland at the base of the neck that produces hormones. Thyroid cancer can happen when there are genetic changes in the thyroid cells, which cause them to grow uncontrollably and produce a lump. One of such genetic changes happens in the RET-activating fusions and mutations, which are key disease drivers in many cancer types, including thyroid cancer. The currently available drugs for treating thyroid cancer are associated with significant side effects, which can lead to a reduction in the effective dose of the medicine taken compared to the recommended dose. There is, therefore, a need for well-tolerated, effective treatments, particularly those that target the genetic mutations that drives the cancer.
Pralsetinib is a once-daily oral therapy designed to selectively and potently inhibit alterations in the RET gene. Early studies have shown that Pralsetinib can have improved selectivity for common RET-activating fusions and mutations when compared to similar therapies in the same class, resulting in manageable safety profile and meaningful clinical activity in patients irrespective of previous treatment history. If licensed, pralsetinib may offer a potent and well-tolerated treatment option for people with thyroid cancer, who currently have few safe and effective treatment options.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts